The combination treatment of venetoclax and A1331825 may be effective in the treatment of IDH2-mutated AML in the absence of PTPN11 mutations, while the combination of venetoclax and S63845 may be effective in AML in the presence of PTPN11 mutations. This evidence concerns the gene IDH2 and acute myeloid leukemia.